Schedule 13G ownership disclosure

Artiva Biotherapeutics, Inc.

Common Stock, $0.0001 par value per share · CUSIP: 04317A107

Event date: 2025-03-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • venBio Global Strategic Fund III, L.P.

    Shares: 1,198,975 · Class: 4.9%

  • VENBIO GLOBAL STRATEGIC GP III, L.P.

    Shares: 1,198,975 · Class: 4.9%

  • VENBIO GLOBAL STRATEGIC GP III, LTD

    Shares: 1,198,975 · Class: 4.9%

  • Adelman Robert J

    Shares: 1,198,975 · Class: 4.9%

  • GOODMAN COREY S

    Shares: 1,198,975 · Class: 4.9%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000905148-25-001783
Form type
SCHEDULE 13G/A
Filer
Artiva Biotherapeutics, Inc.
CIK
CIK 1817241
Filed
May 15, 2025
Reporting period
Mar 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub